Andrew E Place MD PhD
Pediatric Hematologic Oncology
Co-Director, Hematologic Malignancy Program; Dana-Farber/Boston Children's Cancer and Blood Disorders Center Assistant Professor, Harvard Medical School
Join to view full profile
450 Brookline AveDana 3-146Boston, MA 02115
Phone+1 617-632-2313
Dr. Place is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrew Place is a pediatric hematologist/oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Boston Children's Hospital, Dana-Farber Cancer Institute, and Brigham and Women's Hospital. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice 11 years. He specializes in pediatric hematologic oncology and is experienced in developmental therapeutics and relapsed/refractory leukemia.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2009 - 2012- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2006 - 2009
Geisel School of Medicine at DartmouthClass of 2006
Dartmouth CollegePhD, Pharmacology and Toxicology, 1998 - 2004
Certifications & Licensure
FL State Medical License 2022 - Present
NH State Medical License 2022 - 2028
RI State Medical License 2022 - 2028
CT State Medical License 2022 - 2027
MA State Medical License 2009 - 2027
ME State Medical License 2022 - 2027
VT State Medical License 2023 - 2024
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
Publications & Presentations
PubMed
- Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.Susan I Colace, Lauren Pommert, Kasey J Leger, Teresa Rushing, Kristine R Crews
Journal of the National Cancer Institute. 2026-10-19 - Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.Jonathan D Paolino, Kyle Hebert, Jiemin Yang, Christine N Duncan, Steven P Margossian
Blood Advances. 2026-10-13 - Fatal Neuroinvasive Astrovirus VA1 Encephalitis in a Child With High-Risk B-ALL Receiving Blinatumomab.Alaric W D'Souza, Pietro Miozzo, Molly Wilson-Murphy, Andrew E Place, Sudeb Dalai
Pediatric Blood & Cancer. 2026-10-01
Abstracts/Posters
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...Andrew E. Place, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Pediatric Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027September 15th, 2026
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 19th Year in a RowOctober 7th, 2025
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a RowOctober 8th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: